<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HIBERIX- haemophilus influenzae type b <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> 20752 capsular polysaccharide <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid conjugate antigen injection, powder, lyophilized, for solution </strong><br>GlaxoSmithKline Biologicals SA<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use HIBERIX safely and effectively. See full prescribing information for HIBERIX. <br>HIBERIX [Haemophilus b Conjugate Vaccine (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Conjugate)]<br>Solution for Intramuscular Injection<br>Initial U.S. Approval: 2009</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="41%">
<col width="10%">
<tbody class="Headless"><tr class="First Last Toprule">
<td><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<a href="#ID_f252bbf5-e134-4315-b0ac-2e74976ead0d">5.3</a>) </p></td>
<td align="center"><p class="Highlighta">03/2012 </p></td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">HIBERIX is a vaccine indicated for active immunization as a booster dose for the prevention of invasive disease caused by <span class="Italics">Haemophilus influenzae</span> type b. HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday). (<a href="#i4i_indications_id_a56eb37b-d682-40fa-adc0-9f1adff7a4c7">1</a>)  </p>
<p class="Highlighta">No clinical data are available from controlled studies comparing booster immunization with HIBERIX and a US-licensed Haemophilus b Conjugate Vaccine. (<a href="#i4i_indications_id_a56eb37b-d682-40fa-adc0-9f1adff7a4c7">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">A single intramuscular injection (approximately0.5 mL) after reconstitution. (<a href="#i4i_section_id_f1195666-6034-4432-a01a-253fecfa5a10">2.2</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Solution for injection supplied as vials of lyophilized vaccine to be reconstituted with the accompanying saline diluent in prefilled syringes. A single dose, after reconstitution, is approximately 0.5 mL. (<a href="#i4i_dosage_form_strength_id_07a76301-2de2-4150-8365-47fe1907d13d">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) after a previous dose of any <span class="Italics">H. influenzae</span> type b- or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine or any component of HIBERIX. (<a href="#i4i_contraindications_id_e56aef58-5386-4c1a-9ba2-9d1c9045259f">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, the decision to give HIBERIX should be based on potential benefits and risks. (<a href="#i4i_section_id_ad8ce43b-ddc9-48c4-9b70-37c1b7ac8058">5.1</a>)</dd>
<dt>•</dt>
<dd>The tip cap of the prefilled syringes may contain natural rubber latex which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in latex sensitive individuals. (<a href="#i4i_section_id_84559d5e-0769-44cf-9673-bbc248151e4a">5.2</a>, <a href="#i4i_how_supplied_id_89ccb5c8-752c-4cdc-b1bd-9e3c947eb11c">16</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>) can occur in association with administration of injectable vaccines, including HIBERIX. Procedures should be in place to avoid <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> injury and to restore cerebral perfusion following <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. (<a href="#ID_f252bbf5-e134-4315-b0ac-2e74976ead0d">5.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common solicited adverse events (≥20%) were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> at the injection site, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, fussiness, loss of appetite, and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>. (<a href="#i4i_section_id_0066a7eb-b88a-43a1-b8dc-11b486db0018">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or <a href="#_Ref">www.vaers.hhs.gov</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Do not mix HIBERIX with any other vaccine in the same syringe or vial. (<a href="#i4i_section_id_13377089-0a5c-48ec-a556-c7cbeb71e4f7">7.1</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Reconstitution Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Guillain-Barré Syndrome</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Latex</a></h2>
<h2><a href="#section-5.3" class="toc"><span class="XmChange">5.3 <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Preventing and Managing Allergic Vaccine Reactions</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Altered Immunocompetence</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Interference With Laboratory Tests</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immunization</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Interference With Laboratory Tests</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Concomitant Vaccine Administration</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Immunosuppressive Therapies</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 Immunological Evaluation</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 Storage Before Reconstitution</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage After Reconstitution</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_a56eb37b-d682-40fa-adc0-9f1adff7a4c7"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"> HIBERIX<span class="Sup">®</span> is indicated for active immunization as a booster dose for the prevention of invasive disease caused by <span class="Italics">Haemophilus influenzae</span> type b. HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday).</p>
<p> HIBERIX is to be used as a booster dose in children who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primary immunization. HIBERIX is not approved for primary immunization.</p>
<p> The evaluation of effectiveness of HIBERIX as a booster dose was based on immune responses in children using serological endpoints that predict protection from invasive disease due to <span class="Italics">H. influenzae</span> type b <span class="Italics">[see Clinical Pharmacology (12.1) and Clinical Studies (14.1)]</span>. These protective antibody levels have not been evaluated in clinical trials in which a booster dose of HIBERIX is compared to a booster dose of a US-licensed Haemophilus b Conjugate Vaccine in children who previously received a primary series with a US-licensed Haemophilus b Conjugate Vaccine <span class="Italics">[see Clinical Studies (14.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_04337712-14e8-432d-b9af-4b9a376e0307"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3301190-05fe-4f57-8122-604d5ff35a52"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Reconstitution Instructions</h2>
<p class="First"> HIBERIX is to be reconstituted only with the accompanying saline diluent. The reconstituted vaccine should be a clear and colorless solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.</p>
<table width="100%">
<col width="34%">
<col width="33%">
<col width="34%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center">
<a name="ID0EY5AG"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=745ff8df-1618-4b76-9aa1-6f42752c0dda&amp;name=hiberix-spl-graphic-01.jpg">
</td>
<td align="center">
<a name="ID0EEBBG"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=745ff8df-1618-4b76-9aa1-6f42752c0dda&amp;name=hiberix-spl-graphic-02.jpg">
</td>
<td align="center">
<a name="ID0EQDBG"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=745ff8df-1618-4b76-9aa1-6f42752c0dda&amp;name=hiberix-spl-graphic-03.jpg">
</td>
</tr>
<tr class="Botrule Last">
<td><p class="First">Figure 1. Cleanse vial stopper. Attach appropriate needle to accompanying prefilled syringe of saline diluent and insert into vial.</p></td>
<td><p class="First">Figure 2. Transfer entire contents of prefilled syringe into vial. With needle still inserted, vigorously shake the vial.</p></td>
<td><p class="First">Figure 3. After reconstitution, withdraw entire contents of vial (approximately 0.5 mL) and administer by intramuscular injection.</p></td>
</tr>
</tbody>
</table>
<p> After reconstitution, HIBERIX should be administered promptly or stored refrigerated between 2° and 8°C and administered within 24 hours. If the vaccine is not administered promptly, shake the solution vigorously again before injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1195666-6034-4432-a01a-253fecfa5a10"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose and Administration</h2>
<p class="First"> HIBERIX is administered as a single dose <span class="Italics">(approximately 0.5 mL)</span> by intramuscular injection into the anterolateral aspect of the thigh or deltoid.</p>
<p> Do not administer this product intravenously, intradermally, or subcutaneously.</p>
<p> HIBERIX is to be used as a booster dose in children who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primary immunization <span class="Italics">[see Indications and Usage (1)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_07a76301-2de2-4150-8365-47fe1907d13d"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"> HIBERIX is a solution for injection supplied as single-dose vials of lyophilized vaccine to be reconstituted with the accompanying saline diluent in prefilled TIP-LOK<span class="Sup">®</span> syringes. A single dose, after reconstitution, is approximately 0.5 mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e56aef58-5386-4c1a-9ba2-9d1c9045259f"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"> Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) after a previous dose of any <span class="Italics">H. influenzae</span> type b- or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine or any component of the vaccine is a contraindication to administration of HIBERIX <span class="Italics">[see Description (11)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_aa5d787f-2a5e-4694-a0b1-b4f614152a6f"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad8ce43b-ddc9-48c4-9b70-37c1b7ac8058"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Guillain-Barré Syndrome</h2>
<p class="First"> If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, the decision to give any <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine, including HIBERIX, should be based on careful consideration of the potential benefits and possible risks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_84559d5e-0769-44cf-9673-bbc248151e4a"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Latex</h2>
<p class="First"><span class="Italics"> The tip caps of the prefilled syringes may contain natural rubber latex which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in latex sensitive individuals</span> [see How Supplied/Storage and Handling (16)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f252bbf5-e134-4315-b0ac-2e74976ead0d"></a><a name="section-5.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.3 <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>) can occur in association with administration of injectable vaccines, including HIBERIX. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> can be accompanied by transient neurological signs such as <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and tonic-clonic limb movements. Procedures should be in place to avoid <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> injury and to restore cerebral perfusion following <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b9b3f74-1a7b-4f80-b8ce-ab7dffc76a39"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Preventing and Managing Allergic Vaccine Reactions</h2>
<p class="First"> Prior to administration, the healthcare provider should review the patient's immunization history for possible vaccine <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Epinephrine and other appropriate agents used for the control of immediate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> must be immediately available should an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylactic reaction</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7571a39-e2b7-4c48-bea2-9327eaff104d"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Altered Immunocompetence</h2>
<p class="First"> Safety and effectiveness of HIBERIX in immunosuppressed children have not been evaluated. If HIBERIX is administered to immunosuppressed children, including children receiving immunosuppressive therapy, the expected immune response may not be obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f38f7f7b-c566-4e46-a508-95dd923a77d1"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Interference With Laboratory Tests</h2>
<p class="First"> Urine antigen detection may not have a diagnostic value in suspected disease due to H. influenzae type b within 1 to 2 weeks after receipt of a H. influenzae type b-containing vaccine, including HIBERIX [see Drug Interactions (7.1)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d1f3a78-fb08-41b3-b168-6ffba3a5777b"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immunization</h2>
<p class="First"> Immunization with HIBERIX does not substitute for routine <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> immunization.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e774d27e-5d45-44e7-9985-88ff3fef3ad9"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0066a7eb-b88a-43a1-b8dc-11b486db0018"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"> Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice. There is the possibility that broad use of HIBERIX could reveal adverse reactions not observed in clinical trials.</p>
<p> In 7 clinical studies, 1,008 children received HIBERIX as a booster dose following primary vaccination with either HIBERIX (not approved for primary series in US, N = 530), Haemophilus b Conjugate Vaccine manufactured by Sanofi Pasteur SA (N = 235), Haemophilus b Conjugate Vaccine manufactured by Merck &amp; Co., Inc. (N = 26), or Haemophilus b Conjugate Vaccine manufactured by Wyeth Pharmaceuticals Inc. (no longer licensed in the US, N = 217). None of the studies included a comparator group that received a booster dose with a US-licensed Haemophilus b Conjugate Vaccine. Studies were conducted in Europe, Canada, and Latin America. Across these studies, the mean age of subjects at the time of booster vaccination with HIBERIX ranged from 16 to 19 months. At the time of vaccination, 172 (17.1%) subjects were 11 to 14 months of age, 642 (63.7%) subjects were 15 to 18 months of age, and 194 (19.2%) subjects were 19 to 25 months of age. Approximately half of the subjects were male. Among subjects for whom information on race/ethnicity was available, nearly all subjects were white.</p>
<p> In these 7 studies, HIBERIX was administered concomitantly with non-US formulations (containing 2.5 mg 2-phenoxyethanol per dose as preservative) of one of the following US-licensed vaccines: INFANRIX<span class="Sup">®</span> (<span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed) (DTaP), KINRIX<span class="Sup">®</span> (<span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Adsorbed and Inactivated Poliovirus Vaccine) (DTaP-IPV), or PEDIARIX<span class="Sup">®</span> [<span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Adsorbed, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B (Recombinant) and Inactivated Poliovirus Vaccine] (DTaP-HBV-IPV). In the studies, DTaP-IPV and DTaP-HBV-IPV were administered in dosing regimens not approved in the US. Some subjects received DTaP-HBV (GlaxoSmithKline Biologicals, not licensed in US) concomitantly with HIBERIX.</p>
<p><span class="Underline">Solicited Adverse Events:</span> In an open-label, multicenter study conducted in Germany, 371 children received a booster dose of HIBERIX administered concomitantly with DTaP-HBV-IPV. The mean age at the time of vaccination was 16 months. Subjects in this study had previously received a primary series with either HIBERIX (not approved for primary series in US, N = 92), Haemophilus b Conjugate Vaccine manufactured by Sanofi Pasteur SA (N = 96), or Haemophilus b Conjugate Vaccine manufactured by Wyeth Pharmaceuticals Inc. (no longer licensed in the US) (N = 183). All subjects previously received 3 doses of DTaP-HBV-IPV. Information on adverse events was collected by parents/guardians using standardized forms for 4 consecutive days following vaccination with HIBERIX (i.e., day of vaccination and the next 3 days). The reported frequencies of solicited local and general adverse events are presented in Table 1.</p>
<a name="_Refid_8086c13d-d911-4773-a357-e4d6258c3"></a><table width="100%">
<caption><span>Table 1. Percentage of Children With Solicited Local And General Adverse Events Within 4 Days of Vaccination<span class="Sup">a</span> With HIBERIX<span class="Sup">b</span> Coadministered With DTaP-HBV-IPV<span class="Sup">c</span>, Intent to Treat Cohort (N = 371)</span></caption>
<col width="17%">
<col width="6%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">%</span></p>
<p><span class="Bold">Any</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">%</span></p>
<p><span class="Bold">Grade 3</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Local<span class="Sup">d</span></span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">24.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.4<span class="Sup">e</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">20.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1<span class="Sup">f</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">14.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.2<span class="Sup">e</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">General</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><span class="Sup">g</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">34.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fussiness</p></td>
<td class="Botrule Rrule" align="center"><p class="First">25.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.8<span class="Sup">h</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Loss of appetite</p></td>
<td class="Botrule Rrule" align="center"><p class="First">22.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.8<span class="Sup">i</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">21.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.5<span class="Sup">i</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">19.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1<span class="Sup">i</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">14.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.8<span class="Sup">i</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.5<span class="Sup">i</span></p></td>
</tr>
</tbody>
</table>
<p>N = all subjects for whom safety data were available.</p>
<p><span class="Sup">a</span> Within 4 days of vaccination defined as day of vaccination and the next 3 days.</p>
<p><span class="Sup">b</span> In this study, 92 subjects previously received 3 doses of HIBERIX (not approved for primary immunization in the US), 96 subjects previously received 3 doses of a US-licensed Haemophilus b Conjugate Vaccine (manufactured by Sanofi Pasteur SA), and 183 subjects previously received 3 doses of a Haemophilus b Conjugate Vaccine that is no longer licensed in the US.</p>
<p><span class="Sup">c</span> In this study, DTaP-HBV-IPV was given to subjects who previously received 3 doses of DTaP-HBV-IPV. In the US, PEDIARIX is approved for use as a 3-dose primary series; use as a fourth consecutive dose is not approved in the US.</p>
<p><span class="Sup">d</span> Local reactions at the injection site for HIBERIX.</p>
<p><span class="Sup">e</span>Grade 3 <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> defined as &gt;20 mm.</p>
<p><span class="Sup">f</span>Grade 3 <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> defined as causing <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> when limb moved.</p>
<p><span class="Sup">g</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> defined as ≥100.4°F (≥38.0°C) rectally or ≥99.5°F (≥37.5°C) axillary, oral or tympanic; Grade 3 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> defined as &gt;103.1°F (&gt;39.5°C) rectally or &gt;102.2°F (&gt;39.0°C) axillary, oral or tympanic.</p>
<p><span class="Sup">h</span>Grade 3 fussiness defined as persistent <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> and could not be comforted.</p>
<p><span class="Sup">i</span>Grade 3 for these symptoms defined as preventing normal daily activity.</p>
<p><span class="Underline">Serious Adverse Events:</span> Two of 1,008 subjects reported a serious adverse event that occurred in the 31-day period following booster immunization with HIBERIX. One subject developed bilateral <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> 9 days post-vaccination and one subject experienced <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> following accidental drug ingestion 18 days post-vaccination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_32ad0bcd-f423-4429-ae76-522d527822ff"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First"> In addition to reports in clinical trials, worldwide voluntary reports of adverse events received for HIBERIX since market introduction (1996) of this vaccine are listed below. This list includes serious events and/or events which have a plausible causal connection to HIBERIX. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to vaccination.</p>
<p><span class="Underline">General Disorders and Administration Site Conditions:</span> Extensive <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the vaccinated limb, <span class="product-label-link" type="condition" conceptid="4316211" conceptname="Injection site induration">injection site induration</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> (including anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>), <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> (with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), hypotonic-hyporesponsive episode, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or vasovagal responses to injection.</p>
<p><span class="Underline">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>.</p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_79018678-514b-48a5-bd5e-0dc983abd093"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13377089-0a5c-48ec-a556-c7cbeb71e4f7"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Interference With Laboratory Tests</h2>
<p class="First"> Haemophilus b capsular polysaccharide derived from Haemophilus b Conjugate Vaccines has been detected in the urine of some vaccinees.<span class="Sup">1</span> Urine antigen detection may not have a diagnostic value in suspected disease due to <span class="Italics">H. influenzae </span>type b within 1 to 2 weeks after receipt of a <span class="Italics">H. influenzae</span> type b-containing vaccine, including HIBERIX <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff1bc082-602d-47c3-bed9-35f8f882abb0"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Concomitant Vaccine Administration</h2>
<p class="First"> In clinical studies, a booster dose of HIBERIX was administered concomitantly with 1 of the following vaccines: DTaP, DTaP-IPV, DTaP-HBV-IPV, or DTaP-HBV (GlaxoSmithKline Biologicals, not licensed in the US). The formulations of DTaP, DTaP-IPV, and DTaP-HBV-IPV were non-US formulations (containing 2.5 mg 2-phenoxyethanol per dose as preservative) of the following US-licensed vaccines: INFANRIX, KINRIX, and PEDIARIX, respectively. In these studies, DTaP-IPV and DTaP-HBV-IPV were administered in dosing regimens that are not approved in the US. <span class="Italics">[See Adverse Reactions (6.1) and Clinical Studies (14.1).]</span></p>
<p> Sufficient data are not available to confirm lack of interference in immune responses to other vaccines administered concomitantly with HIBERIX.</p>
<p> If HIBERIX is administered concomitantly with other injectable vaccines, they should be given with separate syringes and at different injection sites. HIBERIX should not be mixed with any other vaccine in the same syringe or vial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9b2ad37-cc50-4a84-95ee-96c9b8c4d20e"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Immunosuppressive Therapies</h2>
<p class="First"> Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to HIBERIX.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_d0703d69-fe7e-4e80-b0a6-0f05190c18f7"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2b4a86f8-93a4-4206-b199-ca8be1b4758a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"> Pregnancy Category C</p>
<p> Animal reproduction studies have not been conducted with HIBERIX. It is also not known whether HIBERIX can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_746344af-655b-4e99-9430-8b3871eff14d"></a><a name="section-8.2"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"> Safety and effectiveness of HIBERIX were established in the age group 15 through 18 months on the basis of clinical studies <span class="Italics">[see Adverse Reactions (6.1) and Clinical Studies (14.1)]</span>. Safety and effectiveness of HIBERIX in the age group 19 months through 4 years are supported by evidence in children 15 through 18 months of age. Safety and effectiveness of HIBERIX in children younger than 15 months of age and in children 5 to 16 years of age have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d36ba6db-189c-4e38-84b1-55b3a4675022"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"> HIBERIX [Haemophilus b Conjugate Vaccine (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Conjugate)] is a sterile, lyophilized powder which is reconstituted at the time of use with the accompanying saline diluent for intramuscular injection. HIBERIX contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), a high molecular weight polymer prepared from the <span class="Italics">Haemophilusinfluenzae</span> type b <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> 20,752 grown in a synthetic medium that undergoes heat inactivation and purification. The <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxin, prepared from <span class="Italics">Clostridium tetani</span> grown in a semi-synthetic medium, is detoxified with formaldehyde and purified. The capsular polysaccharide is covalently bound to the <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid. After purification, the conjugate is lyophilized in the presence of lactose as a stabilizer. The diluent for HIBERIX is a sterile saline solution (0.9% sodium chloride) supplied in prefilled TIP-LOK syringes.</p>
<p> When HIBERIX is reconstituted with the accompanying saline diluent, each dose is formulated to contain 10 mcg of purified capsular polysaccharide conjugated to approximately 25 mcg of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, 12.6 mg of lactose, and ≤0.5 mcg of residual formaldehyde.</p>
<p> HIBERIX does not contain preservatives.</p>
<p> The tip caps of the prefilled syringes may contain natural rubber latex. The rubber plungers of the prefilled syringes and the vial stoppers do not contain latex. <span class="Italics">[See How Supplied/Storage and Handling (16).]</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_239b18d3-ee46-4916-9026-929c279c728b"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_133a90ff-4446-44d0-9bd6-d521753305a7"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Italics">Haemophilus influenzae</span> is a gram-negative coccobacillus. Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> that cause invasive disease are type b. <span class="Italics">H. influenzae</span> type b can cause invasive disease such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> and <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.</p>
<p> Specific levels of antibodies to polyribosyl-ribitol-phosphate (anti-PRP) have been shown to correlate with protection against invasive disease due to <span class="Italics">H. influenzae</span> type b. Based on data from passive antibody studies<span class="Sup">2</span> and a clinical efficacy study with unconjugated <span class="Italics">Haemophilus</span> b polysaccharide vaccine<span class="Sup">3</span>, an anti-PRP concentration of 0.15 mcg/mL has been accepted as a minimal protective level. Data from an efficacy study with unconjugated <span class="Italics">Haemophilus</span> b polysaccharide vaccine indicate that an anti-PRP concentration of ≥1.0 mcg/mL predicts protection through at least a 1-year period.<span class="Sup">4,5</span> These antibody levels have been used to evaluate the effectiveness of Haemophilus b Conjugate Vaccines, including HIBERIX.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_19db21ac-4311-4afe-93d4-c6da3634cdb8"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a0cd9ba9-7f2b-49e8-8d5f-fab62d8a82c7"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"> HIBERIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_b37d538b-9219-4746-a352-dc89f815332b"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2330aa97-f013-4d71-a4b7-a099980ec5db"></a><a name="section-12.1"></a><p></p>
<h2>14.1 Immunological Evaluation</h2>
<p class="First"> In 6 clinical studies, the immune response to HIBERIX administered as a booster dose was evaluated in a total of 415 children 12 to 23 months of age. At the time of vaccination, 30 children were 12 to 14 months of age, 316 children were 15 to 18 months of age, and 69 children were 19 to 23 months of age. Among subjects, 43% to 60% were male. Among subjects for whom information on race/ethnicity was available, nearly all subjects were white. None of the studies included a comparator group that received a booster dose with a US-licensed Haemophilus b Conjugate Vaccine. Characteristics of 3 of these studies are presented in Table 2.</p>
<a name="_Refid_8b44e536-656a-4ffd-b9e0-2c6039d51"></a><table width="100%">
<caption><span>Table 2. Characteristics of 3 Open-Label Booster Immunization Studies of HIBERIX</span></caption>
<col width="7%">
<col width="9%">
<col width="22%">
<col width="24%">
<col width="17%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Country</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2">
<p class="First"><span class="Bold">Per Protocol Immunogenicity Cohort</span></p>
<p><span class="Bold">N</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Priming History</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Booster Vaccination With HIBERIX</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Age at Vaccination (months)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Concomitantly Administered Vaccine<span class="Sup">a</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Canada</p></td>
<td class="Botrule Rrule" align="center"><p class="First">42</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">DTaP-HBV-IPV<span class="Sup">b</span> + Haemophilus b Conjugate Vaccine<span class="Sup">c</span></p>
<p>at 2, 4, and 6 months of age</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">16-18</p></td>
<td class="Botrule Rrule" align="center"><p class="First">DTaP-HBV-IPV<span class="Sup">b</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Canada</p></td>
<td class="Botrule Rrule" align="center"><p class="First">64</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">DTaP-IPV<span class="Sup">d</span> + HIBERIX<span class="Sup">e</span></p>
<p>at 2, 4, and 6 months of age</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">16-19</p></td>
<td class="Botrule Rrule" align="center"><p class="First">DTaP-IPV<span class="Sup">d</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Germany</p></td>
<td class="Botrule Rrule" align="center"><p class="First">108</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">DTaP-HBV<span class="Sup">f</span> + HIBERIX<span class="Sup">e</span></p>
<p>at 3, 4, and 5 months of age</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">16-23</p></td>
<td class="Botrule Rrule" align="center"><p class="First">DTaP-HBV<span class="Sup">f</span></p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Administered at a separate site.</p>
<p><span class="Sup">b</span> Non-US formulation equivalent to PEDIARIX with the exception of containing 2.5 mg 2-phenoxyethanol per dose as preservative. In the US, PEDIARIX is approved for use as a 3-dose primary series; use as a fourth consecutive dose is not approved in the US.</p>
<p><span class="Sup">c</span> US-licensed Haemophilus b Conjugate Vaccine manufactured by Sanofi Pasteur SA.</p>
<p><span class="Sup">d</span> Non-US formulation equivalent to KINRIX with the exception of containing 2.5 mg 2-phenoxyethanol per dose as preservative. In the US, KINRIX is approved for use as the fifth dose of DTaP and the fourth dose of IPV in children 4 to 6 years of age previously primed with approved dosing regimens of INFANRIX and/or PEDIARIX. The DTaP-IPV dosing regimen is not approved in the US.</p>
<p><span class="Sup">e</span> In the US, HIBERIX is not approved for primary immunization.</p>
<p><span class="Sup">f</span> Manufactured by GlaxoSmithKline Biologicals (not licensed in the US).</p>
<p> Antibodies to PRP were measured in sera obtained immediately prior to and 1 month after booster vaccination with HIBERIX. Geometric mean concentrations and anti-PRP seroprotection rates are presented in Table 3.</p>
<a name="_Refid_96ceb961-0a71-4981-9adf-43049aa58"></a><table width="100%">
<caption><span>Table 3. Anti-PRP GMCs and Seroprotection Rates Prior to and 1 Month Following a Booster Dose of HIBERIX, Per Protocol Immunogenicity Cohort</span></caption>
<col width="8%">
<col width="8%">
<col width="8%">
<col width="10%">
<col width="8%">
<col width="9%">
<col width="7%">
<col width="8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">Anti-PRP GMC</span></p>
<p><span class="Bold">(mcg/mL)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">% Anti-PRP</span></p>
<p><span class="Bold">≥0.15 mcg/mL</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">% Anti-PRP</span></p>
<p><span class="Bold">≥1.0 mcg/mL</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Pre-</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Post-</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Pre-</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Post-</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Pre-</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Post-</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">1<span class="Sup">a</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">42</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.46</p></td>
<td class="Botrule Rrule" align="center"><p class="First">59.07</p></td>
<td class="Botrule Rrule" align="center"><p class="First">76.2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">100</p></td>
<td class="Botrule Rrule" align="center"><p class="First">35.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">97.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">2<span class="Sup">b</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">63-64</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">47.78</p></td>
<td class="Botrule Rrule" align="center"><p class="First">71.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">100</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">100</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">3<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">108</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.59</p></td>
<td class="Botrule Rrule" align="center"><p class="First">96.12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">77.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">100</p></td>
<td class="Botrule Rrule" align="center"><p class="First">32.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">100</p></td>
</tr>
</tbody>
</table>
<p>GMC = geometric mean antibody concentration.</p>
<p>N = number of children for whom serological results were available for the pre- and post-dose immunological evaluations.</p>
<p>Studies 1, 2, and 3 correspond to Studies 1, 2, and 3, respectively in Table 2.</p>
<p><span class="Sup">a</span> Canadian study in children 16 to 18 months of age who previously received 3 doses of DTaP-HBV-IPV and Haemophilus b Conjugate Vaccine (manufactured by Sanofi Pasteur SA). The booster dose of HIBERIX was coadministered with DTaP-HBV-IPV (a fourth consecutive dose of PEDIARIX is not approved in the US). In this study, pre-vaccination sera may have been obtained up to 1 week prior to booster vaccination with HIBERIX.</p>
<p><span class="Sup">b</span>Canadian study in children 16 to 19 months of age who previously received 3 doses of DTaP-IPV and HIBERIX (not approved for primary immunization in the US). The booster dose of HIBERIX was coadministered with DTaP-IPV. The DTaP-IPV dosing regimen is not approved in the US.</p>
<p><span class="Sup">c</span>German study in children 16 to 23 months of age who previously received 3 doses of DTaP-HBV (GlaxoSmithKline Biologicals, not licensed in the US) and HIBERIX (not approved for primary immunization in the US). The booster dose of HIBERIX was coadministered with DTaP-HBV.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_7d8b95a5-50ac-48ae-80bb-1e3fa8b24c6c"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Rothstein EP, Madore DV, Girone JAC, et al. Comparison of antigenuria after immunization with three <span class="Italics">Haemophilusinfluenzae</span> type b conjugate vaccines. <span class="Italics">Pediatr Infect Dis J</span> 1991;10:311-314.</dd>
<dt>2.</dt>
<dd>Robbins JB, Parke JC, Schneerson R, et al. Quantitative measurement of “natural? and immunization-induced <span class="Italics">Haemophilus influenzae</span> type b capsular polysaccharide antibodies. <span class="Italics">Pediatr Res</span> 1973;7:103-110.</dd>
<dt>3.</dt>
<dd>Peltola H, Käythy H, Sivonen A, et al. <span class="Italics">Haemophilusinfluenzae</span> type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. <span class="Italics">Pediatrics</span> 1977;60:730-737.</dd>
<dt>4.</dt>
<dd>Käythy H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of <span class="Italics">Haemophilusinfluenzae</span> type b. <span class="Italics">J Infect Dis</span> 1983;147:1100.</dd>
<dt>5.</dt>
<dd>Anderson P. The protective level of serum antibodies to the capsular polysaccharide of <span class="Italics">Haemophilusinfluenzae</span> type b. <span class="Italics">J Infect Dis</span> 1984;149:1034.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_89ccb5c8-752c-4cdc-b1bd-9e3c947eb11c"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"> HIBERIX is available in single-dose vials (contains no latex)of lyophilized vaccine, accompanied by disposable prefilled TIP-LOK syringes (may contain latex) (packaged without needles) containing 0.7 mL of saline diluent. The tip caps of the needleless prefilled syringes may contain natural rubber latex.</p>
<p> Supplied as:</p>
<p>NDC 58160-806-01 Vial of lyophilized vaccine in Package of 10: NDC 58160-806-05</p>
<p>NDC 58160-951-02 Syringe containing diluent in Package of 10: NDC 58160-951-11</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2c63e6d-1ca8-43d5-b70b-93342c52e3ec"></a><a name="section-14.1"></a><p></p>
<h2>16.1 Storage Before Reconstitution</h2>
<p class="First"> Lyophilized vaccine vials: Store refrigerated between 2° and 8°C (36° and 46°F). Protect vials from light.</p>
<p> Diluent: Store refrigerated between 2° and 8°C (36° and 46°F) or at a controlled room temperature between 20° and 25°C (68° and 77°F). Do not freeze. Discard if the diluent has been frozen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cecbb7d8-7f10-46d7-9c76-3ddb3fd00ee4"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage After Reconstitution</h2>
<p class="First"> HIBERIX should be administered within 24 hours of reconstitution. After reconstitution, store refrigerated between 2° and 8°C (36° and 46°F). Discard the reconstituted vaccine if not used within 24 hours. Do not freeze. Discard if the vaccine has been frozen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_cf7c4327-b775-49ed-84fa-9ae999c35510"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"> Parents or guardians should be:</p>
<dl>
<dt>•</dt>
<dd>informed of the potential benefits and risks of immunization with HIBERIX.</dd>
<dt>•</dt>
<dd>informed about the potential for adverse reactions that have been temporally associated with administration of HIBERIX or other vaccines containing similar components.</dd>
<dt>•</dt>
<dd>instructed to report any adverse events to their healthcare provider.</dd>
<dt>•</dt>
<dd>given the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8572fbfb-38e1-4715-857c-bb30e0c74821"></a><a name="section-16"></a><p></p>
<p class="First">HIBERIX, INFANRIX, KINRIX, PEDIARIX, and TIP-LOK are registered trademarks of GlaxoSmithKline.</p>
<p>Manufactured by <span class="Bold">GlaxoSmithKline Biologicals</span></p>
<p>Rixensart, Belgium, US License 1617, and</p>
<p>Distributed by <span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, NC 27709</p>
<p>©2012, GlaxoSmithKline. All rights reserved.</p>
<p>March 2012</p>
<p>HRX:4PI</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c784139e-c32e-4649-8a5a-28a9ea2babb9"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 58160-806-05</span></p>
<p><span class="Bold"><span class="Italics">HIBERIX<span class="Sup">®</span></span></span></p>
<p><span class="Bold"><span class="Italics">Haemophilus b Conjugate Vaccine (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Conjugate)</span></span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p>For booster dose only; 15 months through 4 years of age.</p>
<p><span class="Bold">Contents:</span> 10 Vials each containing one dose of Lyophilized Vaccine</p>
<p>Reconstitute only with the accompanying saline diluent.</p>
<p>©2009, GlaxoSmithKline</p>
<p>429670        Rev. 7/09</p>
<div class="Figure">
<a name="id857"></a><img alt="vial carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=745ff8df-1618-4b76-9aa1-6f42752c0dda&amp;name=hiberix-spl-graphic-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HIBERIX 		
					</strong><br><span class="contentTableReg">haemophilus b conjugate vaccine (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid conjugate) injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58160-806</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HAEMOPHILUS INFLUENZAE TYPE B <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 20752 CAPSULAR POLYSACCHARIDE <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOID CONJUGATE ANTIGEN</strong> (HAEMOPHILUS INFLUENZAE TYPE B <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 20752 CAPSULAR POLYSACCHARIDE <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOID CONJUGATE ANTIGEN) </td>
<td class="formItem">HAEMOPHILUS INFLUENZAE TYPE B <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">STRAIN</span> 20752 CAPSULAR POLYSACCHARIDE <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOID CONJUGATE ANTIGEN</td>
<td class="formItem">10 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58160-806-05</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58160-806-01</td>
<td class="formItem">0.5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125347</td>
<td class="formItem">08/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>GlaxoSmithKline Biologicals SA
							(372748392)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>49cd1d5e-681d-41c5-9a68-d9d117463b8f</div>
<div>Set id: 745ff8df-1618-4b76-9aa1-6f42752c0dda</div>
<div>Version: 8</div>
<div>Effective Time: 20120312</div>
</div>
</div> <div class="DistributorName">GlaxoSmithKline Biologicals SA</div></p>
</body></html>
